Germany now saying it will send its top intelligence chiefs to washington next week to try to get some answers from the white house. The spying allegations overshadowing a meeting in belgium. Also today british Prime Minister talking about the leaker, and those who publish what Edward Snowden gave them. What mr. Snowden has effectively done and what some newspapers are assisting him in doing, and that is going to make at it lot more difficult to keep our countries and our people safe. Mike viqueira joins us now live from the white house with more on how the white house is dealing with these spying allegations. Well, they are being relatively tight lipped here. The spokesperson saying the Obama Administration is committed to engaging bilaterally. Yesterday jay carney, reiterating time and time again all of these are being discussed through the appropriate channels. There is no question this is an embarrassing situation for the Obama Administration. Reporter the controversy is growing an
Share this article
Share this article
LIEGE, Belgium, June 3, 2021 /PRNewswire/ Amyl Therapeutics ( Amyl ), a preclinical stage biotechnology company developing its amyloid fibrils specific
technology platform named ClariTY for the treatment of all forms of Amyloidosis, today announced that it has successfully closed a €18.3 million Series A financing. The funding round comprises €8.6 million in equity led by Noshaq - a regional Belgian private-public fund - with support from Merieux Participations, Sambrinvest and other private investors; and €9.7 million in non-dilutive funding from the DG06 – a key policy-design and implementing body for research and innovation policy in the Walloon region of Belgium.
The round is comprised of:
€8.6m in equity led by Noshaq – a regional Belgian private-public fund – with participation from Merieux Participations, Sambrinvest and other private investors; and
€9.7m in non-dilutive funding from the DG06 – a key policy-design and implementing body for research and innovation policy in the Walloon region of Belgium.
Following the closing of the financing, Dr. Pierre Vandepapelière (Amyl’s Co-Founder, CEO and CMO), Florent Gros (Amyl’s Co-Founder and Chairman), Dr. Valérie Calenda (Managing Partner at Merieux Equity Partners), Kenneth Buckfire (President of Miller Buckfire & Co.) and Amel Tounsi (Investment Manager at Noshaq) have joined the Board of Directors.